Project Grant HT9425261E323
Award Date 9/30/26
Completion Date 9/29/28
Dollars Obligated $547K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tacoma, WA 98402, USA
Similar Awards
- Federal Project Grant Award Summary The Geneva Foundation received a $487,800 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective October 1, 2025 through September 30, 2027. The award funds research to define the cellular origins and molecular vulnerabilities of Notch-driven lymphomas. This research initiative contributes to the Defense Health Agency's broader mission of transforming healthcare for service members...
- Federal Grant Award Summary The Geneva Foundation received a $1,009,750 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded August 1, 2025, for a three-year performance period ending July 31, 2028. The award supports genomic and functional characterization of chemoresistance in small cell lung cancer, a research initiative conducted at the foundation's facility in Tacoma, Washington. This project contributes to...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $747,394 Project Grant on April 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research on antagonism-enforced braking system Chimeric Antigen Receptor T-cell (CAR T-cell) therapies for the treatment of TP53-mutant breast cancer. The three-year project, scheduled for completion on March 31, 2029, will be conducted at The Geneva Foundation's facility in...
- Federal Project Grant Award Summary The Defense Health Agency awarded The Geneva Foundation a $999,766 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2029. The award supports research to accelerate personalized T-cell receptor (TCR) immunotherapy for microsatellite-stable colorectal cancer through development of a multimodal prediction model. This research initiative addresses a significant clinical...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a Project Grant of $4.397 million under the Military Medical Research and Development program (CFDA 12.420) on November 1, 2025, with an ultimate completion date of October 31, 2028. This grant funds research on extracorporeal immunomodulation to reduce inflammation after severe burns, inhalation injury, and septicemia. The project addresses critical medical challenges affecting Service Members by...
- Federal Project Grant Award Summary The Geneva Foundation received a $909,510 Project Grant awarded May 1, 2025, by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support precision therapy research for the eradication of brain metastatic breast cancer. The three-year award, with an ultimate completion date of April 30, 2028, will be performed at the foundation's Tacoma, Washington facility. This research initiative aligns with the...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Geneva Foundation a $488,276 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the development of antagonism-enforced braking system chimeric antigen receptor T-cell (CAR T-cell) therapeutics for the treatment of TP53-mutant breast cancer. The three-year project, initiated April 1, 2026 and concluding March 31, 2029, represents DHA's investment in advancing cancer immunotherapy...
- Federal Project Grant Award Summary The Defense Health Agency awarded The Geneva Foundation a $637,335 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026 through June 30, 2029 to conduct research on the intratumoral microbiome in acral melanoma. This three-year research initiative will investigate the microbial communities present within acral melanoma tumors and their potential role in disease progression, immune response, and...
- The Defense Health Agency (DHA) awarded The Geneva Foundation a $559,224 Project Grant on May 15, 2026, through the Military Medical Research and Development program (CFDA 12.420) to support research on in vivo selection of prometastatic tumor microbiota in pancreatic cancer. The three-year project, concluding May 14, 2029, will be conducted at The Geneva Foundation's facility in Tacoma, Washington. This award supports basic and applied biomedical research aligned with the DHA's mission to...
- The Geneva Foundation received a $453,029 Project Grant award from the Department of the Army Medical Command on February 1, 2021 to improve the therapeutic index of antibody drug conjugates targeting metastatic breast cancer. Funded through January 31, 2024 under the Military Medical Research and Development program (CFDA 12.420), this award will support the Foundation's work to transform healthcare and investigate medical solutions for the battlefield by developing more effective targeted...